Arcus Biosciences Puts Casdatifan Kidney Cancer Data At Center Stage [Yahoo! Finance]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker analyses that support casdatifan's mechanism and potential clinical benefit in kidney cancer patients. Arcus also highlighted progress across its broader oncology and inflammation pipeline, with multiple Phase 3 programs underway or planned. For you as an investor, this update puts the clinical profile of casdatifan front and center in the kidney cancer drug class. Arcus focuses on oncology and inflammation, and the latest data add another piece to how its HIF-2a program fits within a crowded renal cell carcinoma treatment field. The company is using casdatifan alongside a wider set of assets that target different
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences (RCUS) had its price target raised by Citigroup Inc. from $44.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- Arcus Biosciences (RCUS) had its price target raised by Leerink Partners from $36.00 to $49.00. They now have an "outperform" rating on the stock.MarketBeat
- Arcus Biosciences (RCUS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Arcus Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Participate in Two Upcoming Investor ConferencesBusiness Wire
RCUS
Earnings
- 2/25/26 - Beat
RCUS
Sec Filings
- 2/25/26 - Form S-3ASR
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- RCUS's page on the SEC website